BPH Global (ASX:BP8) Full Year 2024 Results

Key Financial Results

• Revenue: AU$110.0k (up by AU$109.6k from FY 2023).

• Net loss: AU$1.98m (loss narrowed by 49% from FY 2023).

• AU$0.006 loss per share (improved from AU$0.016 loss in FY 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

In the last 12 months, the only revenue segment was Sourcing, Producing, Marketing and Selling of Traditional Medicines contributing AU$110.0k. Notably, cost of sales worth AU$91.7k amounted to 83% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to AU$1.48m (74% of total expenses). Explore how BP8's revenue and expenses shape its earnings.

BPH Global shares are up 50% from a week ago.

Risk Analysis

We should say that we've discovered 6 warning signs for BPH Global (5 make us uncomfortable!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.